STAT+: 5 burning questions on Trump’s latest deals with drugmakers

STAT PlusPolitics 5 burning questions on Trump’s latest deals with drugmakers Agreements leave open questions for patients, companies, and policymakers alike Manage alerts for this article Email this article Share this article By Daniel Payne, Elaine Chen, and John WilkersonSept. 1, 2026 Daniel Payne[email protected]Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care.

Confidential tips can be sent on Signal at danielp.100.Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.John Wilkerson[email protected]John writes about the politics of health care, and he is the author of the twice-weekly D.C.

Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. The Trump administration on Monday announced a second group of pharmaceutical companies had pledged to lower drug prices to levels comparable to those in other nations.

But the details of the deals, which President Trump has touted from the White House as one of the most important breakthroughs in health care, aren’t public. Some key questions remain — including whether all the companies in the second wave would avoid tariffs or otherwise mandatory Medicare drug pricing pilot programs. (The White House did not respond to requests for comment about these questions.)Advertisement Here are some of the biggest questions about the agreements.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In biotechnology, Drug prices, Pharmaceuticals, STAT+, White House Submit a correction requestReprints Daniel Payne Washington Correspondent Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100.

Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

John Wilkerson Washington Correspondent John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.

Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout September 1, 2026 STAT Plus: Novartis gets multiple sclerosis win with BTK inhibitor D.C. Diagnosis September 1, 2026 STAT Plus: Will House delay Trump plan to politicize NIH grants? Advertisement Pharma August 31, 2026 STAT Plus: Trump strikes nine more deals with drugmakers to lower prices The Readout August 31, 2026 STAT Plus: Can a pregnancy hormone steer a cardiovascular treatment?

Biotech August 31, 2026 STAT Plus: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy Subscriber Picks